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Abstract 
Microglia are a special type of supporting 
cells in the nervous system. between the 
functions they perform are myelin 
production, structural support, regulation 
of extracellular fluid, glial scar formation 
among others. This cell type for its 
versatility, is also related to pathological 
events, where his multiple roles and the 
release of proinflammatory factors can 
contribute to understand especially in 
traumatic brain injury, as secondary injury 
and the healing process, important aspects 
the context of brain injury.  
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Introduction 
The role of microglia in the 
neurotrauma has been under continuous 
debate, researches have been trying to state 
how microglia-mediated inflammation can 
contribute to recovery of function after 
trauma, or fell in secondary injury. 
Microglia, are resident cells of the brain 
involved in regulatory processes critical for 
development, maintenance of the neural 
environment, injury, and repair (1). 
Microglia derives from mesodermal 
precursor cells of hemapoietic lineage that 
populate the central nervous system (CNS) 
in early development. Resident microglia 
cells are turned over slowly, and are 
replenished throughout adult life by 
proliferation (2), and represent the resident 
macrophages of the CNS, accounting for 
10% of the adult glial cell population in the 
normal brain (3). Morphologically distinct 
from neurons and astrocytes, these cells 
were classified by Cajal in 1913 as a third 
element of CNS (4). Del Río Hortega 
made a further distinction between 
microglia and other glial cells in 1932. At 
that time the morphological classification of 
microglia allowed three kinds of states: 
ramified, intermediate forms, and ameboid 
(5). Recent studies have evolved the 
classification to include a functional 
connotation like M1 and M2 phenotypes 
(6). These phenotypes, allows them to 
actively participate in pathological processes 
by changing their morphology, expressing 
various antigens and becoming phagocytic 
(7).  
Microglia cells function as sentinels for 
innate immunity in the CNS continually 
monitoring and screening the extracellular 
environment, walling off areas of the CNS 
from foreign tissue, and removing damaged 
or dead cells (1), to achieve that, these cells 
express various sets of pattern recognition 
receptors (PRRs) in response to pathogen-
associated molecular patterns (PAMPs) that 
include Toll-like receptors (TLRs; e. g: 
TLR-4) and inflammasomes (8). Very 
often, microglia cells provide the first line 
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defense against invading germs, and 
interacting with neurons and other glial 
cells, they can be the first sense of critical 
changes in the neuronal activity.  
Although microglial cells are thought to 
contribute to most pathological conditions, 
including CNS infections, 
neuroinflammatory lesions, brain tumors, 
and neurodegenerative diseases, their exact 
role in CNS development, homeostasis, 
and disease remains poorly understood (3). 
Regarding to neurotrauma, exists a strongly 
investigated feature, and that is the 
histological evidence of a prominent 
microglial activation (9). Currently there 
are many medical conditions under 
research because of the microglia activation 
in their pathological processes (10, 11, 12, 
13).  
This review will explore the current 
concepts and researches on microglial 
responses to CNS traumatic injury and also 
will be discussed the differential role of 
microglia.  
General response of microglia to injury 
For microglial activation no large 
amount of tissue damage is required; 
alterations of neural electric transmission or 
extracellular electrolyte composition and 
the release of soluble factors normally 
confined to the intracellular compartment 
are sufficient to trigger microglia cells 
activation.  
In the healthy mature CNS, microglia 
have a ramified morphology, a small soma 
with fine cellular processes, this appearance 
has been associated with microglial “resting 
state”. When CNS is insulted, either for 
trauma, infection, ischemia, neurodege-
nerative disease o an altered neuronal 
activity, microglia can evoke rapid and 
intense changes in their cell shape, gene 
expression and functional behavior, all 
these changes conjure the “microglial 
activation” (14), as will be discussed later 
more precisely, microglia cells respond by 
detecting lipopolysaccharide (LPS) (8), 
beta-amyloid (Aβ) (15), thrombin, IFN-γ, 
and other proinflammatory cytokines (16).  
In this late state, microglia suffer a 
morphological transformation, induction of 
a wide range of soluble factors, like 
cytokines, free radicals and nitric oxide, 
acquire a phagocytic phenotype (17) to clear 
tissue debris, damaged cells, or germs, and 
get physically associated with injured 
neurons. Microglial activation may result in 
expression of MHC (18) antigens and 
costimulatory molecules and in the capacity 
of microglia to act as antigen presenting 
cells. Microglial activation has key features: 
first, these cells react to all CNS 
pathologies, no matter if they are acute or 
chronic. Second, the response evoked is 
graded, and can range from very slight 
morphological changes accompanied by 
minor immunological activation, to the 
development of full-blown tissue 
macrophages with the associated expression 
of an entire battery of membrane bound 
and soluble immunologically relevant 
molecules (19). Because of the “immune 
privilege” (20) of the CNS, i. e., that the 
brain parenchyma has to protect itself from 
the potentially detrimental consequences of 
an immune reaction, the microglial 
activation is a highly regulated process. It is 
important to recognize the fact that 
microglia in “resting state”, actively scan 
and monitor the extracellular environment 
by pinocytosis (21), always ready to 
transform to a state of “activity”, in which 
microglia primarily serve for support and 
protection. So, the transition from a 
“resting” mode to an executive state thereby 
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represents a shift in activities rather than 
“activation” phenomenon, then, there are 
no periods of inactivity.  
Once microglial cell “activation” occurs, 
it starts with an emergency like response, 
such as defense oriented functions, i. e., 
combat an infection or to limit additional 
damage after injury. Eventually, the 
activated population, convert to a repair-
oriented response, for tissue reparation.  
Although much effort has been directed 
toward characterizing the fundamental 
properties of an activated microglial cell, 
surprisingly little is known about the 
intrinsic molecular mechanisms that 
program the functional state of these cells 
in either the healthy or the diseased CNS 
(22), but these molecular mechanisms can 
be grouped to produce five stages: 
proliferation, migration, secretion of 
soluble products and electrophysiological 
changes.  
- Proliferation: 
Irrespective of the type of CNS lesion, 
microglial cells show an early proliferative 
response, usually proliferation indices, i. e., 
the number of actively proliferating 
microglial cells divided by the total number 
of microglial cells, peak around 3–5 days 
after a lesion (19). This proliferative 
response rapidly declines subsequently and 
approaches control levels 7-15 days after 
injury; but even after the zenith of the 
proliferation index, the total number of 
microglial cells can remain elevated, and 
depending on the type of injury, will still 
being significantly higher than pre-lesion 
values around a month after an 
experimental injury (23, 24, 25).  
The proliferation of microglial cells is 
triggered by damage to adjacent neurons, 
and deafferentation of central neurons by 
peripheral axotomy is a sufficient stimulus 
to induce it. A number of different factors 
have been shown to play important roles in 
the initiation of microglial proliferation but 
even actually is an incompletely answered 
world. In laboratory experiments have been 
demonstrated the presence of macrophage-
colony stimulating factor (M-CSF) as a 
driver of the cell cycle of microglia, 
inducing their proliferation (26). Purinergic 
receptor P2X7 also controls microglial 
proliferation (27). Others microglial 
mitogens are the granulocyte/monocyte 
colony-stimulating factor (GM-CSF), 
brain-derived neurotrophic factor (BDNF), 
neurotrophin (NT)-3, IL-1, IL-5, and 
chemokines (e. g., fractalkine and its 
receptor CXC3CL1) (28, 29, 30, 31, 32, 33). 
In the other hand, the proliferation 
regulation or inhibition seems to be exerted 
by the Transforming growth factor beta 
(TGF-β), mainly produced by activated 
astrocytes (34). In microglial cells 
proliferation, also are important the cell-cell 
interactions, particularly with neurons (35), 
which have key roles in delivery of 
regulatory signals, in part through the 
glycoprotein OX-2 (36). Microglia are 
equippated with glutamate-, purinergic-, 
acetylcholine-, adrenergic-, dopamine-, 
neurokinin-, serotoninergic-, opioid- and 
gamma-amino-butyric-acid-receptors, 
implicating that for their function is 
important the neuronal activity detection, 
but, microglia neurotransmitter receptor 
aren’t in a specialized region in close 
apposition to neurotransmitter release sites. 
Spatial proximity to synapses can be 
attained transiently; the long-term 
association is not likely since microglia cells 
are highly motile in resting and activated 
states (21). Neuron-microglia 
communication relies mostly on release of 
signaling molecules from extrasynaptic 
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axonal varicosities, as well as their diffusion 
from synapses.  
- Migration 
Microglia processes are capable of rapid 
extension (≈1. 25 mm/min) towards sites 
of acute CNS damage (37). The main 
candidate for a chemoattractant sensed by 
microglia is adenosine triphosphate [ATP; 
involves G(i/o) proteins and the mitogen-
activated protein kinase 
(MAPK)/extracellular signal-regulated 
kinase (ERK)-dependent pathway] (38) 
through microglial P2Y12 receptors (39) 
and an outward potassium current (40). 
Neuropeptides such as angiotensin II, 
bradykinin (controlled by a G(i/o)-protein-
independent pathway), endothelin, galanin 
[induces microglial migration in a similar 
way to bradykinin, but induces intracellular 
Ca(2+) mobilization by inositol-3, 4, 5-
trisphosphate (InsP(3))-dependent Ca(2+) 
release from the intracellular store] and 
neurotensin are also chemoattractants for 
microglia. The fact that there are different 
intracellular signaling cascades indicates 
that chemoattractants control distinct 
microglial functions. Nitric oxide (NO) 
also is an additional guidance cue involved 
in microglia migration.  
- Secretion of soluble factors 
These are derived mainly from the 
activated microglia, and consist of 
cytokines, proteases, free radicals and 
growth factors. Proinflammatory cytokines, 
which are closely involved in various 
diseases (including trauma, ischemia, 
Alzheimer's disease, epilepsy, and others), 
play important roles in the facilitation of 
activated microglia for astrocytic activation 
(34). Among the most important cytokines 
is IL-1 (41), showing neurotoxic actions, 
and stimulating astrocytes and other 
microglial cells in paracrine and autocrine 
way. Its receptor is also founded both in 
neurons and glial cells. IL-1 induces 
expression of other proinflammatory 
mediators like IL-6 (42), and TNF-α (43), 
thus this interleukin seems to play a 
regulating role in the concert of cytokines, 
and binding results in activation of a series 
of intracellular adaptor molecules, mitogen 
activated protein (MAP) kinases and the 
transcription factor, nuclear factor kappa B 
(NF-kB), leading to changes in gene 
expression. The first cells to express IL-1 
are microglia, but other brain cells 
(astrocytes, invading immune cells, vascular 
cells and probably neurons) can also 
produce IL-1 (41). Once the 
microenvironment of the CNS becomes 
activated, local cells also produce 
proinflammatory cytokines, chemokines 
and upregulate inmunomodulatory surface 
markers. These changes in turn decrease 
the stringency of the blood-brain barrier, 
allowing entry of other soluble factors and 
peripheral immune cells, including 
macrophages, natural killer cells and 
lymphocytes. Proteases are also very 
important after CNS injury, because they 
mediate tissue damage and invasion of 
blood-derived immunocompetent cells. A 
factor recognized as a potential neurotoxic 
microglial secretion product is tissue-
plasminogen activator (t-PA); it aggravates 
neuronal injury after ischemia (44). One 
key mediators of cytotoxicity in the CNS 
secreted by microglia is NO (45), this 
molecule displays a wide array of biological 
activities, ranging from cytotoxicity to 
neuroprotective effects and 
neurotransmission (46). NO acts directly as 
neurotoxic via excitotoxic mechanisms (47). 
Little is known about cellular mechanisms 
regulating reactive oxygen species (ROS) 
production by activated microglia under 
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pathological conditions, but, in microglia 
can produce ROS in different ways, e. g., 
NADPH oxidase, mitochondria or xanthine 
oxidase (48).  
Phagocytic and cytotoxic functions of 
microglia are also triggered during CNS 
injury. Upon activation, microglia 
upregulate opsonic receptors including 
complement receptors (CR1, CR3, CR4) 
and Fc gamma receptors (I, II, III), which 
enhance phagocytic activity by binding to 
complement components and 
immunoglobulin fragments respectively 
(36).  
- Electrophysiological changes 
In the ion channels relays key functions 
of microglial physiology, for example, 
deramification of microglial cells in culture 
was inhibited by blockade of nonselective 
cation channels, this suggest that cation 
influx through such channels increases the 
intracellular osmolarity with a subsequent 
osmotic entry of water and cell swelling 
(49), and the ramification, or the 
adquisition of a amoeboid shape, is likely o 
be associated with stretch-activated Cl- 
channels (50). Also has been observed that 
voltage- and/or Ca2+-activated K+ 
channels regulate microglial proliferation 
(51), migration (52, 53), cytokine secretion 
(54, 55, 56), production of free radicals (57, 
58, 59). Strikingly, the intracellular 
conversion of pre-IL-1b to biologically 
active IL-1b is dependent for the decrease 
the cytoplasmic K+ concentration (60) and 
blockade of delayed outward rectifier K+ 
channels resulted in an inhibition of LPL-
stimulated microglial IL-1- release (61). 
Chloride channels have been found to be 
involved in microglial proliferation (62, 63), 
production of ROS (64, 65), iNOS 
expression and nitric oxide production (66), 
migration (52), phagocytosis (67) and 
ramification (68). During NADPH oxidase 
mediated respiratory burst of microglia are 
important the proton channels for charge 
compensation (69). Calcium has been 
evidenced to participate in transmission of 
brain-damage signals to microglia through 
long-range waves, this type of waves is 
induced by glutamate and is independent of 
ATP (70). What happens after activation is 
an even less known fact than the microglial 
activation. Microglial activation when no 
longer needed, finishes being an 
unremarkable phenomenon, and not even 
much noticed, but, may be some residual 
effects (71). When being challenged again, 
the experienced microglia could behave 
differently, and this could explain some 
chronically related problems like age-
related dysfunction or a neurodegenerative 
process (72, 17). However this behavior 
could be a protective effect, because the 
affected cells have been prepared by the 
former activation to respond quickly and 
efficiently in a second injury.  
Microglia: dual behavior? 
Exists the concept of secondary neuronal 
damage, i. e., microglia-mediated 
inflammation fell in secondary neuronal 
injury, and is in part built over the base that 
immunocompetent cells can aggravate 
neuronal demise, but whether microglial 
cells have a dual role, supportive or 
detrimental in neurotrauma and in others 
CNS acute or chronic pathologies has been 
the key question of almost a century. Has 
been stated that microglial behavior 
depends on several factors: the kind of 
stress and damage signals, the 
duration/timing of an impact, the 
microenvironment, the interaction with 
other cell types and, interestingly, even the 
age of an organism (73). There are a 
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contrast between the potentially neurotoxic 
substances and the growth factors secreted 
by microglia, but it is impossible to predict 
the kind of microglia behavior (benefit or 
harm to surviving neurons) that will be 
induced by the lesion in an acute and 
chronic way. Macrophages and microglia 
can be classified into at least two subsets 
with distinct molecular phenotypes and 
effector functions depending on the 
activation pathway. The “activated” 
proinflammatory M1 macrophages, 
activated by LPS and by the 
proinflammatory cytokine IFN-γ, express 
CD86 and CD16/32 and produce high 
amounts of oxidative metabolites (NO and 
superoxide), proteases and proinflammatory 
cytokines. They play a central role in host 
defense against pathogens and tumor cells, 
and they can also damage healthy cells such 
as neurons and glial cells. In contrast, M2 
macrophages are ‘alternatively activated’, 
anti-inflammatory macrophages induced by 
IL-4 and IL-13, and they express CD206 
and arginase 1. The latter downregulate 
inflammation and promote tissue 
remodeling/repair and angiogenesis (73, 6). 
As previously mentioned, microglia can 
both produce and respond to cytokines, 
these can be either neuroprotective [e. g. 
IL-10, tumor growth factor (TGF)-β, 
TNF-α] and/or neurotoxic (e. g. IL-1, 
TNF-α, IFN-γ) (74). At high levels TNF-α 
is neurotoxic, but at low levels it can be 
neuroprotective (75). In models that 
simulate chronic systemic inflammation has 
been shown that microglia in young mice 
protect dopaminergic neurons against LPS, 
but in the old mice, microglia promote the 
death cell (76).  
Beneficial responses 
Almost all studies for evaluation of the 
role of microglia in pathological 
circumstances have been performed using 
in vitro cultured microglia, whereby there 
are limitations because those only shows 
one cell phenotype simulating a 
physiological or pathological condition, 
also, these models lacks of the 
microenvironmental interactions with other 
cells like neurons and astrocytes. Thanks to 
the phagocytic function, microglia can enter 
damaged brain regions and remove toxic 
detritus, invading pathogens and cell debris. 
In case of stimulation of TLR by pathogens 
is induced a proinflammatory reaction but, 
in cases of brain injury, the recognizing of 
phosphatidylserine of the cell membrane of 
damaged neurons induces an anti-
inflammatory reaction (74). Also in brain 
injury, microglial shows other beneficial 
activities like promoting protection to 
neurons (77), reestablishment of the neural 
environment (78), and has been evidenced 
that insufficient removal of myelin by 
microglia impairs the recruitment of 
oligodendrocyte precursor cells and induces 
an arrest of oligodendrocyte differentiation 
(78). Some cytokines secrete by microglia 
have an important role in protection, IL-6 
can act on astrocytes and induce brain tissue 
repair (79), the IL-10 is an inhibitory 
cytokine of microglial apoptosis (80) and 
the TGF-β also can be neuroprotective (81, 
82, 83) and it is elevated after injury (84, 
85). These pleiotropic cytokines have 
central roles in vascular remodeling, 
immune suppression, immune homeostasis 
and repair after injury (86, 87, 88, 89). 
Furthermore, both TGF-β and IL-10 
inhibit macrophage and microglia activation 
by downregulating the expression of 
molecules associated with antigen 
presentation and production of 
proinflammatory cytokines, chemokines, 
and nitric and oxygen free radicals (90, 91, 
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92). Microglia promote neuroplasticity and 
axonal regeneration, in addition to the 
monitoring and pruning of synapses (93, 
94). Microglia can modify neural networks 
in multiple ways: promoting neuronal cell 
death, influencing neural circuitry by 
neuroplastic reorganization or synaptic 
stripping (95). Activated microglia also 
enhance angiogenesis (96, 97, 98). Has been 
suggested that T cells, once activated (by 
encountering their relevant antigen-
presenting cells), control the local innate 
response by activating resident microglia in 
a well-controlled way (99). They can also 
express neuroprotective proteins such as 
neurotrophins and glutamate transporters 
(100, 101). The latter transporters might 
help to reduce glutamate toxicity via uptake 
of glutamate.  
Detrimental responses 
Microglia have been implicated as a 
contributor to neuron damage, in models of 
excitotoxic cell death, phagocytic microglia 
contribute to neuronal degeneration and 
cell loss. Microglia can release glutamate, 
this neurotransmitter is well known to 
trigger excitotoxic neurodegeneration and 
cell death of astrocytes and 
oligodendrocytes (102, 103, 104, 105).  
The exact mechanism leading to 
microglial overactivation is still not fully 
understood, but glial-neuronal crosstalk 
seems to be central (106), but because of 
activated microglia can release cytotoxic 
factors such as NO and ROS and secrete 
pro-inflammatory cytokines that can 
potentially damage neurons, 
oligodendrocytes or extracellular matrix 
structures directly or indirectly, i. e., 
activating astrocytes trough IL-1-mediated 
neurotoxicity (107, 34, 108) have been 
considered as a “double-edged sword”, and 
inhibition of its functions have been 
beneficial in some circumstances (109, 110, 
19, 111). Evidence is available to show the 
presence of activated microglia and their 
ability to induce cell death in the immature 
white matter, both in oligodendrocytes 
precursors and in astrocytes (112, 113).  
The ROS (NO, hydrogen peroxide, 
superoxide) can kill invading microbes but 
also can induce neural damage and reactive 
gliosis (74). The intracellular ROS derived 
from NADPH oxidase play special roles in 
neurodegeneration for his dual functions 
(114, 115). The ROS released 
extracellularly can be directly toxic for 
neurons, especially dopaminergic ones, and 
when intracellular ROS concentrations 
raise, can alter the signaling cascade leading 
to microglia activation (116, 117, 118, 119). 
Microglia have been related to the 
progressive nature of neurodegenerative 
diseases through their capacity to be 
chronically activated by neuron death and 
fuelling, a self-renewing cycle of microglial 
activation followed by further neuron 
damage (reactive microgliosis). This self-
propelling cycle in microglial cells is 
possibly mediated by intracellular ROS and 
NO when they become activated by LPS 
(120). The activation of the prostaglandin 
E2 receptor of the prostaglandin E2 
pathway can lead to microglia-induced 
paracrine neurotoxicity (121).  
The acute microglia response is not 
considered detrimental, but when it became 
persistent, i.e., chronic microglial 
activation, is considered to be the most 
damaging response of microglia to injury 
through the previously stated mechanisms, 
that in the interaction damaged neuron-
hyperactivated microglia create a self-
propagating feedback loop that leads to an 
aberrant prolonged microglial activation 
and to neuronal death, chronic progression 
and neurodegeneration.  
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